SightLine Closes Second Fund, Oversubscribed with $107 Million in Commitments

SightLine Closes Second Fund, Oversubscribed with $107 Million in Commitments

sightline nfSightLine Partners, an investor in late-stage medical technology companies, has closed SightLine Healthcare Opportunity Fund II, LP with $107 million of capital commitments. Fund II was oversubscribed, exceeding its original target of $100 million. The new fund will make secondary direct investments in medical technology companies.

“We are encouraged by the tremendous interest in the fund, from an excellent group of investors. Our investment strategy of providing creative financial alternatives to existing investors in late-stage medical technology companies has been well-received in the market, as evidenced by the fund’s over-subscription,” said Buzz Benson, Managing Director at SightLine. “There continues to be a critical financing gap for many high-quality companies in the med-tech sector and SightLine Partners is uniquely qualified to offer solutions to both the companies and investors facing this challenging environment.”

SightLine’s investment focus since early 2009 has been to provide financial alternatives to existing investors in late-stage companies who may not have sufficient capital to support current portfolio companies and risk having their preferred ownership converted to common, or wish to achieve liquidity on certain portfolio companies, need to reduce or eliminate future funding requirements, or want to rebalance and reallocate fund reserves.

“Our investment strategy is well-suited to the current financing environment in the medical technology marketplace, where many late-stage companies are requiring more capital and time to achieve a successful exit. We continue to see opportunities which have a near term clarity of exit and which provide the best potential for risk-adjusted returns,” said Joe Biller, Managing Director at SightLine.

SightLine Partners manages a series of private equity funds that provide financing to later stage medical device and diagnostic companies and financial alternatives to the existing investors in these companies. The firm raised its first fund in 2009 and is based in Minneapolis (

© 2013 PEPD • Private Equity’s Leading News Magazine • 8-9-13

To search in site, type your keyword and hit enter